Aletta, a groundbreaking autonomous blood-draw device, has recently received approval from the U.S. Food and Drug Administration for use outside of hospital settings. Developed by the Dutch firm Vitestro, this innovative system combines imaging technologies with robotics and artificial intelligence to perform blood draws with minimal human intervention.
How Aletta Works
Using a series of advanced techniques, Aletta begins by directing a near-infrared light to scan the inner elbow for veins. Following this, an alcohol puff sanitizes the skin, and an ultrasound probe maps the depth and curvature of the veins. To ensure accuracy, a Doppler sensor assesses blood flow direction, helping to avoid arteries. Once the optimal vein is identified, a cuff tightens around the upper arm, and the needle is inserted to collect blood into tubes, each rotated precisely nine times before withdrawal. The entire process is executed without any human contact.
Clinical Validation and Performance
In a clinical trial involving over 1,600 participants in the Netherlands, Aletta successfully drew blood on the first attempt in 94.5 percent of cases, even among individuals with challenging veins, such as those with obesity or the elderly. When the device could not locate a suitable vein, a human phlebotomist was available to assist. Experts have noted that Aletta’s performance is comparable to that of trained phlebotomists, with minimal complications due to its built-in safety features.
Addressing Staffing Challenges
With a median annual turnover rate of nearly 25 percent among phlebotomists and a vacancy rate close to 10 percent, staffing shortages pose significant challenges for clinical labs. Aletta’s design allows a single phlebotomist to supervise multiple machines, potentially alleviating these operational issues and enhancing lab capacity for routine diagnostic testing.
Considerations of Equity in Technology
Despite its promising capabilities, Aletta does face challenges, particularly regarding skin tone bias. The near-infrared light used for vein mapping may not perform as well on individuals with darker skin due to melanin absorption. However, Vitestro asserts that the ultrasound component of Aletta mitigates this risk, as it operates independently of skin pigmentation. The company claims the technology is effective for all skin tones, although further validation is necessary to ensure equitable performance across diverse populations.
Aletta, named after the pioneering physician Aletta Jacobs, signifies a significant advancement in automated blood collection technology. While the device is currently focused on the blood-drawing process, there are aspirations for future developments that could integrate further testing capabilities. Vitestro plans to launch Aletta in Europe next year, with the U.S. market to follow shortly thereafter.
This article was produced by NeonPulse.today using human and AI-assisted editorial processes, based on publicly available information. Content may be edited for clarity and style.
